Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Hypercholesterolemia Clinical Trial

— V-DIFFERENCE  

Official title:

Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With Hypercholesterolemia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05192941
• Other study ID #: CKJX839A12402
• Secondary ID: 2021-003759-40
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: April 8, 2022
• Est. completion date: March 26, 2025

Study information

• Verified date: June 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia

Description:

The purpose of this study is to demonstrate the superiority of inclisiran compared to placebo, both on top of ongoing individually optimized lipid-lowering therapy (LLT), on reaching a participant's LDL-C target (< 55 mg/dL or < 70 mg/dL, depending on the cardiovascular risk category, according to the 2019 ESC/EAS guidelines for the management of dyslipidemias as well as on patient-relevant safety, tolerability outcomes and quality of life.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1775
• Est. completion date: March 26, 2025
• Est. primary completion date: June 11, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

1. Written informed consent must be obtained before any assessment is performed.

2. Male or female participants =18 years of age.

3. Participants categorized as very high or high CV risk, as defined below:

•Very high risk participants with at least one of the following: A. Documented Atherosclerotic Cardiovascular Disease (ASCVD) i) Acute Coronary Syndrome: Unstable angina or myocardial infarction ii) Stable angina iii) Unequivocally documented ASCVD upon prior imaging v) Stroke and Transient Ischaemic Attack (TIA) vi) Peripheral Artery Disease (PAD) B. Diabetes mellitus (DM) with target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), or at least = 3 major risk factors, or early onset of Type 1 DM of long duration (> 20 years) C. A calculated SCORE2 = 7.5% for age < 50 years; SCORE2 = 10% for age 50-69 years; SCORE2-OP = 15% for age = 70 years to estimate 10-year risk of fatal and non-fatal CVD D. Pre-existing diagnosis of heterozygous familial hypercholesterolemia (HeFH) with ASCVD or with another major risk factor.

OR

•High risk participants with at least one of the following: A. Markedly elevated single risk factors, in particular total cholesterol > 310 mg/dL, LDL-C > 190 mg/dL, or blood pressure = 180/110 mmHg B. Pre-existing diagnosis of HeFH without other major risk factors C. DM without target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), with DM duration = 10 years or other additional risk factor D. Moderate chronic kidney disease (eGFR 30-59 mL/min/1.73m2) E. A calculated SCORE2 2.5 to <7.5% for age under 50 years; SCORE2 5 to <10% for age 50-69 years; SCORE2-OP 7.5 to <15% for age =70 years to estimate 10-year risk of fatal and non-fatal CVD as defined by the cardiovascular risk categories in the 2019 ESC/EAS guideline (Mach et al 2020)

4. LDL-C levels:

1. in participants with very high cardiovascular risk: serum LDL-C =55 mg/dL

2. in participants with high cardiovascular risk: serum LDL-C =70 mg/dL

5. Participant on a stable dose of a statin for = 30 days.

6. Up to approximately 20% of total participants can be on a stable dose (for = 30 days prior to screening) of another LLT on top of statin such as a cholesterol absorbing inhibitor or a bile acid sequestrant, or alternatively, an adenosine triphosphate citrate lyase (ACL) inhibitor, as indicated.

7. Fasting triglyceride < 400 mg/dL.

At Baseline:

8. Fasting triglyceride < 400 mg/dL.

9. Before randomization, despite being treated with the individual MTD of a statin for = 30 days and, if applicable, with another LLT on top of statin (stable for = 30 days),

1. in participants with very high cardiovascular risk: serum LDL-C = 55mg/dL.

2. in participants with high cardiovascular risk: serum LDL-C = 70mg/dL.

Key Exclusion Criteria: Participants meeting any of the following criteria are not eligible for inclusion in this study.

1. Severe concomitant non-CV disease that is expected to reduce life expectancy to less than 2 years at screening or baseline visit.

2. Participants on more than one other lipid-lowering drug on top of statin at screening visit.

3. Pre-existing diagnosis of homozygous familial hypercholesterolemia at screening or baseline visit.

4. Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome at screening or baseline visit.

5. Previous (within 90 days of screening), current or planned treatment with a monoclonal antibody (mAb) directed towards PCSK9 (e.g. evolocumab, alirocumab) at screening or baseline visit.

6. Previous exposure to inclisiran or any other non-mAb PCSK9 targeted therapy, either as an investigational or marketed drug within 2 years prior to screening or baseline visit.

7. Previous, current or planned treatment with LDL-apheresis at screening or baseline visit.

8. Participants with known intolerance to rosuvastatin at screening or baseline visit.

9. History of hypersensitivity to any of the study treatments, inclisiran or rosuvastatin, or its excipients or to drugs of similar chemical classes at screening or baseline visit.

10. Participants taking gemfibrozil at screening or baseline visit.

11. Liver and CK: (a) Active liver disease defined as any current infectious, neoplastic, or metabolic pathology of the liver or (b) unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST) elevation >3x ULN, or total bilirubin elevation > 2x ULN (except for participants with Gilbert's syndrome), or (c) creatine kinase (CK) >5x ULN at screening or baseline visit.

12. Participant with severe renal impairment defined by eGFR <30 mL/min/1.73m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at screening or baseline visit.

13. Acute coronary syndrome, ischemic stroke or TIA, coronary revascularization or peripheral arterial revascularization procedure or amputation due to atherosclerotic disease < 3 months prior to the screening or baseline visit.

14. Planned or expected cardiac, cerebrovascular or peripheral artery surgery or coronary revascularization within the study duration.

15. Heart failure New York Heart Association (NYHA) class IV at screening or baseline visit.

16. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy (excluding systemic adjuvant therapies given to prevent cancer recurrence eg: hormonotherapy for prostate or breast cancer) during the 3 years prior to screening or baseline visit.

17. Participant with myopathy at screening or baseline visit.

18. Participant receiving concomitant ciclosporin at screening or baseline visit.

19. Participants that are predisposed to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).

20. Participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose-malabsorption.

21. Unwillingness or inability (e.g. physical or cognitive) to comply with study procedures (including study visits, fasting blood draws and compliance with study treatment regimens), and medication administration (injections) and schedule. Participant should be able and willing to read, understand and answer questionnaires.

22. Any surgical or medical condition, which in the opinion of the investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study at screening or baseline visit.

23. Use of other investigational drugs within 5 half-lives, 30 days or until the expected pharmacodynamic effect has returned to baseline (e.g. biologics), whichever is longer or longer if required by local regulation, prior to screening visit.

24. Pregnant or nursing (lactating) women at screening or baseline visit.

25. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment, which includes rosuvastatin, and for 5 days (= 5 times the terminal half-life of rosuvastatin) after stopping medication. Highly effective contraception methods include:

• Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.

• Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.

• Use of oral, (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women are considered not of child bearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessments and she is considered not of child bearing potential.

If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the local ICF.

Related Conditions & MeSH terms

• Hypercholesterolemia

Intervention

Drug:
• Inclisiran Sodium
Subcutaneously injected on Day 1, Day 90, and Day 270
• Placebo
Placebo to inclisiran 300 mg subcutaneously

Locations

Country	Name	City	State
Bulgaria	Novartis Investigative Site	Burgas
Bulgaria	Novartis Investigative Site	Gabrovo
Bulgaria	Novartis Investigative Site	Pleven
Bulgaria	Novartis Investigative Site	Plovdiv
Bulgaria	Novartis Investigative Site	Ruse
Bulgaria	Novartis Investigative Site	Sofia
Bulgaria	Novartis Investigative Site	Sofia
Bulgaria	Novartis Investigative Site	Sofia
Bulgaria	Novartis Investigative Site	Sofia
Bulgaria	Novartis Investigative Site	Stara Zagora
Bulgaria	Novartis Investigative Site	Varna
Bulgaria	Novartis Investigative Site	Veliko Tarnovo
Czechia	Novartis Investigative Site	Chlumec nad Cidlinou
Czechia	Novartis Investigative Site	Hlucin
Czechia	Novartis Investigative Site	Hodonin
Czechia	Novartis Investigative Site	Melnik
Czechia	Novartis Investigative Site	Olomouc
Czechia	Novartis Investigative Site	Olomouc
Czechia	Novartis Investigative Site	Pardubice	Czech Republic
Czechia	Novartis Investigative Site	Prerov	Olomoucky Kraj
Czechia	Novartis Investigative Site	Slany
Czechia	Novartis Investigative Site	Trutnov	CZE
Estonia	Novartis Investigative Site	Parnu
Estonia	Novartis Investigative Site	Tallinn
Estonia	Novartis Investigative Site	Tallinn
Estonia	Novartis Investigative Site	Tartu
France	Novartis Investigative Site	Amiens
France	Novartis Investigative Site	Chambery cedex
France	Novartis Investigative Site	Le Chesnay
France	Novartis Investigative Site	Le Kremlin Bicetre
France	Novartis Investigative Site	Lille
France	Novartis Investigative Site	Marseille
France	Novartis Investigative Site	Paris 13
France	Novartis Investigative Site	St Herblain
France	Novartis Investigative Site	Valenciennes
Germany	Novartis Investigative Site	Bad Gottleuba	Sachsen
Germany	Novartis Investigative Site	Bad Homburg
Germany	Novartis Investigative Site	Bad Krozingen
Germany	Novartis Investigative Site	Bad Oeynhausen
Germany	Novartis Investigative Site	Bamberg
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Bochum
Germany	Novartis Investigative Site	Bremen
Germany	Novartis Investigative Site	Coburg
Germany	Novartis Investigative Site	Dessau-Roßlau
Germany	Novartis Investigative Site	Dresden
Germany	Novartis Investigative Site	Dresden	Saxonia
Germany	Novartis Investigative Site	Duisburg
Germany	Novartis Investigative Site	Erfurt
Germany	Novartis Investigative Site	Erfurt
Germany	Novartis Investigative Site	Essen
Germany	Novartis Investigative Site	Essen
Germany	Novartis Investigative Site	Essen
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Fulda
Germany	Novartis Investigative Site	Gelnhausen
Germany	Novartis Investigative Site	Gladbeck
Germany	Novartis Investigative Site	Gottingen
Germany	Novartis Investigative Site	Hamburg
Germany	Novartis Investigative Site	Hamburg
Germany	Novartis Investigative Site	Hannover	Niedersachsen
Germany	Novartis Investigative Site	Hannover	Niedersachsen
Germany	Novartis Investigative Site	Hassloch
Germany	Novartis Investigative Site	Hennigsdorf
Germany	Novartis Investigative Site	Hoyerswerda
Germany	Novartis Investigative Site	Kaiserslautern	Rhineland-Palatinate
Germany	Novartis Investigative Site	Kassel
Germany	Novartis Investigative Site	Kiel
Germany	Novartis Investigative Site	Koeln
Germany	Novartis Investigative Site	Koln
Germany	Novartis Investigative Site	Langen
Germany	Novartis Investigative Site	Leipzig
Germany	Novartis Investigative Site	Lichtenfels
Germany	Novartis Investigative Site	Loehne
Germany	Novartis Investigative Site	Lueneburg
Germany	Novartis Investigative Site	Magdeburg
Germany	Novartis Investigative Site	Magdeburg
Germany	Novartis Investigative Site	Mainz
Germany	Novartis Investigative Site	Mannheim
Germany	Novartis Investigative Site	Mannheim	Baden Wuerttemberg
Germany	Novartis Investigative Site	Markkleeberg
Germany	Novartis Investigative Site	Muehldorf
Germany	Novartis Investigative Site	Muenchen
Germany	Novartis Investigative Site	Muenster
Germany	Novartis Investigative Site	Nuremberg
Germany	Novartis Investigative Site	Papenburg
Germany	Novartis Investigative Site	Pirna
Germany	Novartis Investigative Site	Potsdam
Germany	Novartis Investigative Site	Regensburg	Bavaria
Germany	Novartis Investigative Site	Reinfeld
Germany	Novartis Investigative Site	Rostock
Germany	Novartis Investigative Site	Ruedersdorf
Germany	Novartis Investigative Site	Saint Ingbert - Oberwuerzbach
Germany	Novartis Investigative Site	Schleswig	Schleswig-Holstein
Germany	Novartis Investigative Site	Singen
Germany	Novartis Investigative Site	Stuttgart
Germany	Novartis Investigative Site	Stuttgart
Germany	Novartis Investigative Site	Wallerfing
Germany	Novartis Investigative Site	Warendorf
Germany	Novartis Investigative Site	Winsen	Lower Saxony
Germany	Novartis Investigative Site	Wuppertal
Latvia	Novartis Investigative Site	Daugavpils
Latvia	Novartis Investigative Site	Ogre
Latvia	Novartis Investigative Site	Riga
Latvia	Novartis Investigative Site	Riga
Latvia	Novartis Investigative Site	Riga
Latvia	Novartis Investigative Site	Riga
Poland	Novartis Investigative Site	Gdynia
Poland	Novartis Investigative Site	Katowice
Poland	Novartis Investigative Site	Krakow
Poland	Novartis Investigative Site	Krakow	Maloposkie
Poland	Novartis Investigative Site	Krosno
Poland	Novartis Investigative Site	Rzeszow
Poland	Novartis Investigative Site	Skierniewice
Poland	Novartis Investigative Site	Szczecin	Zachodniopomorskie
Poland	Novartis Investigative Site	Tarnow	Malopolskie
Spain	Novartis Investigative Site	Barcelona	Catalunya
Spain	Novartis Investigative Site	Barcelona	Catalunya
Spain	Novartis Investigative Site	Cordoba	Andalucia
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Malaga	Andalucia
Spain	Novartis Investigative Site	Oviedo	Asturias
Spain	Novartis Investigative Site	San Sebastian de los Reyes	Madrid
Spain	Novartis Investigative Site	Sanlucar de Barrameda	Andalucia
Spain	Novartis Investigative Site	Sevilla	Andalucia
Spain	Novartis Investigative Site	Sevilla	Andalucia

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Bulgaria,  Czechia,  Estonia,  France,  Germany,  Latvia,  Poland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants achieving individual LDL-C target (<55 mg/dL or <70 mg/dL)	Inclisiran on top of ongoing individually optimized lipid-lowering therapy (LLT) compared to placebo on top of ongoing individually optimized LLT on reaching a participant's individual LDL-C target as measured by the proportion of participants achieving individual LDL-C target (<55mg/dL or < 70 mg/dL) at day 90.	Day 90
Secondary	Relative percentage change from baseline to mean LDL-C level over the double-blind treatment period	Inclisiran on top of ongoing individually optimized LLT compared to placebo on top of ongoing individualized LLT on: reducing mean LDL-C levels over the double-blind study period.	Baseline to Day 360
Secondary	Proportion of participants experiencing at least one Muscle-related adverse event (AE) as defined in the Standardized MedDRA Queries (SMQ)	Participants experiencing at least one muscle-related AE as defined in the SMQ rhabdomyolysis/myopathy from day 1 to day 360.	Baseline to Day 360
Secondary	Proportion of participants experiencing self-reported pain	Annualized number of days pain is experienced using pain diary	Baseline to Day 360
Secondary	Change from baseline in Short-Form Brief Pain Inventory (SF-BPI) pain severity score to Day 360	Pain-related quality of life at day 360 using the SF-BPI	Baseline to Day 360
Secondary	Change from baseline in Short-Form Brief Pain Inventory (SF-BPI) pain interference score at Day 360	Pain related quality of life at day 360 using the SF-BPI	Baseline to day 360
Secondary	Proportion of participants with clinically relevant change in Short-Form Brief Pain Inventory (SF-BPI) pain severity score from baseline to day 360.	Pain-related quality of life at day 360 using the SF-BPI	Baseline to Day 360
Secondary	Proportion of participants with clinically relevant change in Short-Form Brief Pain Inventory (SF-BPI) pain interference score from baseline to day 360	Pain-related quality of life at day 360 using the SF-BPI	Baseline to Day 360